Introduction
Hepatocellular carcinoma (HCC) is a common malignancy of the liver with a poor prognosis. HCC is treated with local ablation, surgical resection, transcatheter arterial chemoembolization and systemic administration of chemotherapeutic agents (1, 2) . The HCC tissue obtains nutrients and oxygen from blood vessels by the process of angiogenesis (3, 4) . Vascular endothelial cells proliferate by activating the mitogen-activated protein (MAP) kinase pathway, which acts downstream of the vascular endothelial cell growth factor (VEGF) receptor (5) . Sorafenib, a multikinase inhibitor of VEGF, inhibits the MAP kinase pathway and is used to treat HCC (6, 7) . Despite the sorafenib treatment, >25% of patients with HCC succumb from disease progression (8) . Thus, it is necessary to investigate alternative drugs/reagents alone or in combination with sorafenib that can inhibit the signaling pathways involved in the proliferation of HCC.
Mesenchymal-epithelial transition factor (c-Met) is a receptor of the hepatocyte growth factor (HGF) (9) . When HGF binds to c-Met, it stimulates downstream signaling via the phosphatidylinositol-3 kinase pathway and MAP kinase. Since c-Met is upregulated in HCC tissues compared to the surrounding normal tissues (10, 11) ,
, are considered to be promising candidates for the treatment of HCC (12) . SU11274 competes with adenosine triphosphate to bind to the activation loop of c-Met (13) . SU11274 is known to suppress the proliferation of HCC cells (14) , and if SU11274 can also suppress angiogenesis, the anti-tumor effects are expected to be stronger.
Thus, the aim of the present study was to establish a co-culture of HCC and human umbilical vein endothelial cells (HUVECs) as an in vitro model of the HCC tissue and to investigate the anti-tumor effects of SU11274.
Materials and methods
Ethical statement. The study was approved by the Ethics Committee of National Hospital Organization Shimoshizu Hospital (Yotsukaido, Japan). Human fetal and adult liver RNA were collected with informed consent from the donors Hematoxylin and eosin (H&E) staining. The cells were spread onto 4-well chambers (Beckton Dickinson, Franklin Lakes, NJ, USA), fixed with 100% methanol at room temperature and stained with H&E staining (Muto Pure Chemicals Co., Ltd., Tokyo, Japan). The specimens were observed and images were captured using an AX80 microscope (Olympus).
Co-culture of HLF or PLC/PRL/5 cells with HUVECs.
HUVECs were spread at a density of 1.9x10 4 cells onto each well of a 24-well plate coated with matrigel (Becton Dickinson) at the density of each well. After 1-day culture in EGM, the medium was discarded and 1.9x10 4 HLF cells or PLC/PRL/5 cells were spread onto each well. The cells were cultured in DMEM supplemented with 10% FBS.
Immunostaining. Serial sections of human healthy adult liver (64-year-old male) and HCC tissue (60-year-old female) (BioChain) were deparaffinized, autoclaved and incubated with hydrogen peroxide, followed by 2% FBS in phosphate-buffered saline (PBS; washing buffer) for 30 min. Following an overnight incubation with rabbit monoclonal anti-c-Met antibody (1:300; Cell Signaling Technology, Danvers, MA, USA), the specimens were rinsed with PBS and incubated with horseradish peroxidase-labeled anti-rabbit antibody (1:2,000; GE Healthcare, Pittsburgh, PA, USA) for 2 h. Subsequently, diaminobenzidine (Dako, Glostrup, Denmark) was applied to the tissue sections as a chromogen and the nuclei were stained with hematoxylin for 15 sec. The specimens were observed and the images were captured under an AX80 microscope (Olympus). A specimen of HCC tissue incubated without the primary antibody was used as a negative control. 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR).
The cells were spread in 6-well plates (Asahi Techno Glass) and cultured until they reached 80% confluency. SU11274 was added to the media and 48 h later, total RNA was isolated using a kit (Isogen; Nippon Gene, Tokyo, Japan). Complimentary DNA was synthesized using SuperScript III and oligo(dT) primers (Life Technologies), as per the manufacturer's instructions. Total RNA from adult human healthy liver was purchased from Clontech Laboratories, Inc. The PCR primers and product sizes were as follows: c-Met 77 [NM_000245; 5'-CATTGGGGAGCACTATGTC-3' (forward), 5'-TGT 78 CCACCTCATCATCAGCG-3' (reverse); 110 basepairs (bp)], cyclin D1 (NM_053056; 5'-AGAGGCGGAGGA GAACAAACAG-3', 5'-AGGCGGTAGTAGGACAGGAAG TTG-3'; 180 bp) and RPL19 (BC095445; 5'-CGAATGCCAG AGAAGGTCAC-3', 5'-CCATGAGAATCCGCTTGTTT-3'; 157 bp). RT-qPCR was performed at 40 cycles consisting of denaturing for 5 sec and annealing-extension for 5 sec. RPL19 primers were used as the internal controls. RT-qPCR was performed using the Fast SYBR-Green Master mix (Life Technologies) in the MiniOpticon system (Bio-Rad). The expression level of the genes was analyzed automatically with the system. The expression levels were normalized against that of 0 µM.
Statistical analyses.
One-way analysis of variance was performed with JMP 10.0.2 (SAS Institute, Cary, NC, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

c-Met expression.
The expression of c-Met was analyzed immunohistochemically in 99 surgical specimens of adult healthy liver and HCC samples from 100 that were commercially available. In the absence of the anti-c-Met antibody, HCC tissues did not show any staining (Fig. 1A) . While the cell membrane of hepatocytes in the normal liver was weakly positive for c-Met (Fig. 1B) , the cell membrane and cytoplasm of cells in the HCC tissue were positive (Fig. 1C) . These data indicate that c-Met is upregulated in HCC cells as compared to the normal hepatocytes.
Subsequently, RT-qPCR was performed to assess the expression level of c-Met in the HCC cell lines and HUVECs (Fig. 2) . The expression levels of c-Met in HLE, HLF, PLC/PRL/5, Hep3B, Huh-6, HepG2, adult healthy liver and HUVECs were 4.43±0.50, 1.61±0.18, 3.70±0.08, 0.81±0.18, 6.60±1.29, 1.06±0.35, 1.00±0.09 and 88.8±17.3 (mean ± standard deviation), respectively. Except in Hep3B cells, the expression of c-Met was higher in all the HCC cell lines and HUVECs as compared to the adult healthy liver.
c-Met inhibition by SU11274.
To address the possibility that inhibition of c-Met suppresses cell proliferation, SU11274 was added to the media and the MTS assay was performed. SU11274 was found to suppress the proliferation of HLF cells in a dose-dependent manner and reached 11.0±9.4% (P<0.05) with 30 µM SU11274 as compared to 0 µM (Fig. 3A) . SU11274 (30 µM) suppressed the proliferation of PLC/PRL/5 cells (Fig. 3B) and HUVECs (Fig. 3C) to 46.5±30.7 (P<0.05) and 29.4±5.0%, as compared to 0 µM (P<0.05), respectively.
To investigate the mechanism of cell proliferation suppression by SU11274, the expression level of cyclin D1 was analyzed by RT-qPCR and was found to decrease to 45.1±11.6% (P<0.05) with 30 µM SU11274 in HLF cells, as (Fig. 4A) . The expression level of cyclin D1 decreased to 30.1±10.3% (P<0.05) of SU11274 in PLC/PRL/5 cells, as compared to 0 µM (Fig. 4B) .
In addition, H&E staining was performed to observe the morphological changes of the cells cultured with or without SU11274. Compared to HLF (Fig. 5A ) and PLC/PRL/5 cells (Fig. 5C ) without SU11274 treatment, apoptotic cells were observed with 30 µM SU11274 treatment (Fig. 5B and D) .
Co-cultures of HLF (Fig. 6A) or PLC/PRL/5 cells (Fig. 6C ) with HUVECs were established to analyze the possibility that SU11274 damages the co-culture used as an in vitro model of hepatoma tissues. Three days after the addition of 30 µM SU11274, the morphology of the co-cultures of HLF (Fig. 6B) or PLC/PRL/5 cells (Fig. 6D ) with HUVECs were found to be damaged and as a result, all the cells died.
Discussion
SU11274 suppresses proliferation and induces apoptosis of HCC cells (15) . In the present study, proliferation of HCC cells was suppressed via the downregulation of cyclin D1, a protein involved in cell cycle progression (16, 17) . These results indicate that SU11274 can suppress cell cycle progression. In addition, H&E staining showed apoptosis in cells cultured with SU11274. SU11274 is known to activate caspase-3 (15) . Taken together, these data indicate that SU11274 suppresses the proliferation of HLF and PLC cells by downregulating cyclin D1 and inducing apoptosis.
c-Met is expressed in vascular endothelial cells and is upregulated along with HGF in response to environmental stress (18, 19) . The results of the present study show that c-Met The data clearly show that these co-cultures were damaged by SU11274 treatment, indicating that SU11274 may be useful for the suppression of proliferation of HCC cells, as well as angiogenesis.
In conclusion, except for Hep3B, c-Met is highly expressed in hepatoma cells and HUVECs. SU11274 (30 µM) suppresses the proliferation of HLF, PLC/PRL/5 and HUVECs and it was found that 30 µM SU11274 damaged the co-culture of HLF or PLC/PRL/5 cells with HUVECs.
